度普利尤单抗治疗特应性皮炎:结膜炎与严重感染风险
该研究利用美国理赔数据开展队列研究,经1:1倾向评分匹配比较特应性皮炎患者启用度普利尤单抗、甲氨蝶呤、环孢素或霉酚酸酯后6个月结膜炎与严重感染风险。度普利尤单抗组严重感染风险低,但结膜炎风险较甲氨蝶呤及霉酚酸酯明显升高,临床需重视管理。
要点
- 度普利尤单抗6个月任何结膜炎风险为6.5%,高于甲氨蝶呤的3.3%。
- 倾向评分匹配后度普利尤单抗较甲氨蝶呤结膜炎RR为2.45(95%CI 1.47-4.08)。
- 度普利尤单抗严重感染风险为0.6%,与甲氨蝶呤相近(RR 0.90)。
核心结论
- 度普利尤单抗严重感染风险低,但与临床相关的结膜炎风险升高,实践中需加以管理。
研究设计与样本
- 采用美国理赔数据的队列研究,比较特应性皮炎患者启用度普利尤单抗、甲氨蝶呤、环孢素或霉酚酸酯后的6个月风险。
- 经1:1倾向评分匹配后计算相对风险(RR)。
- 识别度普利尤单抗1775例、甲氨蝶呤1034例、环孢素186例、霉酚酸酯257例使用者。
主要发现
- 6个月任何结膜炎风险:度普利尤单抗6.5%、甲氨蝶呤3.3%、环孢素4.8%、霉酚酸酯1.2%。
- 倾向评分匹配后度普利尤单抗较甲氨蝶呤结膜炎RR为2.45(95%CI 1.47-4.08)。
- 度普利尤单抗较环孢素结膜炎RR为1.56(95%CI 0.69-3.50),较霉酚酸酯RR为7.00(95%CI 2.12-23.2)。
- 严重感染风险度普利尤单抗0.6%、甲氨蝶呤1.0%,RR为0.90(95%CI 0.37-2.20)。
临床怎么用
- 启用度普利尤单抗前应告知结膜炎风险,治疗中监测眼部症状并及时处理。
- 度普利尤单抗严重感染风险低,可作为需长期系统治疗患者的考虑选项。
局限性
- 分析基于少量事件,且存在监测差异的担忧。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Dupilumab is an effective treatment for moderate to severe atopic dermatitis (AD) with limited safety data in clinical practice. OBJECTIVE: To assess the 6-month risk of conjunctivitis and serious infections in patients with AD who initiated dupilumab. METHODS: In a cohort study using US claims data, we compared the risk of conjunctivitis and serious infections in patients with AD who initiated either dupilumab, methotrexate (MTX), cyclosporine, or mycophenolate. Relative risks (RRs) were computed after 1:1 propensity score matching. RESULTS: We identified 1775 dupilumab, 1034 MTX, 186 cyclosporine, and 257 mycophenolate users. The 6-month risk for any conjunctivitis was 6.5% for dupilumab, 3.3% for MTX, 4.8% for cyclosporine, and 1.2% for mycophenolate initiators. After PS matching, the RR of any conjunctivitis was increased in dupilumab users versus MTX (RR, 2.45; 95% confidence interval [CI], 1.47-4.08), versus cyclosporine (RR, 1.56; 95% CI, 0.69-3.50), and versus mycophenolate (RR, 7.00; 95% CI, 2.12-23.2). The risk of serious infection was 0.6% in dupilumab and 1.0% in MTX initiators (RR, 0.90; 95% CI, 0.37-2.20). LIMITATIONS: Analyses were based on few events, and differential surveillance is a concern. CONCLUSIONS: Although dupilumab shows a low risk of serious infections, it is associated with a clinically meaningful increase in conjunctivitis that needs to be managed in practice.
引用
- Schneeweiss MC, Kim SC, Wyss R, et al. Dupilumab and the risk of conjunctivitis and serious infection in patients with atopic dermatitis: A propensity score-matched cohort study. J Am Acad Dermatol. 2020. PMID: 33038471. doi:10.1016/j.jaad.2020.09.084
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。